Dallas, TX -- (SBWIRE) -- 02/01/2013 -- A complete overview of every segment within this report. This summary includes an abridged competitive analysis, partial numerical data, CAGRS, and qualitative synopses. In 2012, the U.S. interventional cardiology devices market was valued at over $3.5 billion, a 1.6% increase over 2011.
Advancements in specific technologies and practices such as drug management, drug-eluting stents, specialty guidewires, micro-introducer sheaths, fractional flow reserve guidewires and various imaging modalities will account for a great deal of the growth in the total market for interventional cardiology devices in the United States. Many of the established standard items have become commodities and are close to homogeneous in their substitutability. Thus it has been and will continue to be the role of new or specialized devices that receive positive clinical trials to act as catalysts for growth and to increase the market share of companies that are able to capitalize on the opportunity. For established items such as angioplasty accessory kits, companies will be able to utilize distribution networks as well as the competitive advantage that is provided by the bundling of multiple items.
Scope:
This report pertains to a forecast period of 10 years (2009 - 2019) for the U.S.
Report Contents:
- Competitor Analysis
- Identified Strategic Opportunities
- Market Overview by Segment
- Trend Analysis by Segment
- Market Drivers & Limiters
- Mergers & Acquisitions
- Customer Feedback and Market Monitoring
Main Segments Included:
- Drug-eluting stents
- Bare-metal stents
- Percutaneous transluminal coronary angioplasty (PTCA)
- Cutting balloons catheters
- Balloon-inflation devices
- Angioplasty accessory kits
- Interventional catheters and guidewires
- Diagnostic catheters and guidewires
- Coronary introducer sheaths
- Embolic protection devices
- Atherectomy devices
- Thrombectomy devices
- Chronic total occlusion (CTO) devices
- Vascular closure devices (VCDs)
- Intravascular ultrasound (IVUS) catheters
- Potential markets for vulnerable plaque screening
Companies Included:
- AngioDynamics
- Spectranetics
- Argon Medical
- Volcano Therapeutics
- AccessClosure
- Merit Medical Systems
- B. Braun
- C. R. Bard
- Marine Polymer Technologies
- Smiths Medical
- Teleflex Medical
- AngioScore FlowCardia
- Asahi Medical
- BostonScientific
- Abbott Laboratories
- St.Jude Medical
- Medtronic
- Cordis
- Cook Medical
- Vascular Solutions
- MedRAD Interventional/Possis
- Terumo
- Covidien
- Galt Medical
Buy your copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=218224. Contact sales@reportsandreports.com for further information.
Connect US:
Twitter: https://twitter.com/marketsreports
Facebook: http://www.facebook.com/pages/ReportsnReports/191441427571689
Google Plus: https://plus.google.com/u/0/111656568937629536321/posts
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)